---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-25-002817"
form_type: "8-K"
ticker: "BBNX"
cik: "0001674632"
company_name: "Beta Bionics, Inc."
filed_at: "2025-05-06T23:59:59+00:00"
generated_at: "2026-05-22T12:44:39.408571+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Beta Bionics Q1 revenue up 36% to $17.6M; net loss widens; raises 2025 guidance

## Summary
- Net sales $17.6M (+36% YoY); DME $13.8M (+14%), PBP $3.8M (+360%).
- Installed customer base 19,151 (+291%); 3,853 new patient starts (+48%).
- Gross margin 50.9% (down 482 bps); operating loss $18.6M; net loss $28.7M.
- Cash and investments $295.5M as of March 31, 2025.
- Raised full-year 2025 annual guidance (specific numeric targets not in excerpt).

## SEC filing metadata
- accession: 0001171843-25-002817
- form_type: 8-K
- ticker: BBNX
- cik: 0001674632
- company_name: Beta Bionics, Inc.
- filed_at: 2025-05-06T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1674632/000117184325002817/0001171843-25-002817-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1674632/000117184325002817/f8k_050625.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-25-002817
- JSON: https://secwatch.observer/filing/0001171843-25-002817.json
- Plain text: https://secwatch.observer/filing/0001171843-25-002817.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.